Zacks Investment Research downgraded shares of GTX (NASDAQ:GTXI) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.

According to Zacks, “GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx’s lead candidate is enobosarm, a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. GTx is also evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important. “

A number of other brokerages have also weighed in on GTXI. Robert W. Baird assumed coverage on shares of GTX in a report on Tuesday, November 21st. They set an outperform rating and a $17.00 price objective for the company. Stifel Nicolaus assumed coverage on shares of GTX in a report on Thursday, November 9th. They set a buy rating for the company.

Shares of GTX (NASDAQ GTXI) opened at $11.81 on Wednesday. The stock has a market cap of $254.41, a PE ratio of -6.75 and a beta of 1.77. GTX has a twelve month low of $2.73 and a twelve month high of $13.35.

GTX (NASDAQ:GTXI) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.25). equities analysts forecast that GTX will post -1.61 earnings per share for the current year.

In related news, VP Henry Patton Doggrell sold 4,965 shares of GTX stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $11.33, for a total transaction of $56,253.45. Following the completion of the sale, the vice president now owns 54,804 shares in the company, valued at approximately $620,929.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jason T. Shackelford sold 3,090 shares of GTX stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $11.33, for a total transaction of $35,009.70. Following the sale, the insider now owns 31,111 shares of the company’s stock, valued at approximately $352,487.63. The disclosure for this sale can be found here. Insiders have sold a total of 15,364 shares of company stock valued at $174,074 in the last quarter. 41.20% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp bought a new stake in shares of GTX in the 2nd quarter valued at about $124,000. Caxton Corp bought a new stake in shares of GTX in the 3rd quarter valued at about $531,000. Finally, Abingworth LLP bought a new stake in shares of GTX in the 3rd quarter valued at about $2,781,000. Institutional investors and hedge funds own 11.57% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “GTX (GTXI) Lowered to “Sell” at Zacks Investment Research” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/gtx-gtxi-lowered-to-sell-at-zacks-investment-research/1806453.html.

GTX Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Get a free copy of the Zacks research report on GTX (GTXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with Analyst Ratings Network's FREE daily email newsletter.